These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7777855)

  • 21. A semiparametric mixture model for analyzing clustered competing risks data.
    Naskar M; Das K; Ibrahim JG
    Biometrics; 2005 Sep; 61(3):729-37. PubMed ID: 16135024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an immunoassay for differentiating human immunodeficiency virus infections--from vaccine-induced immune response in Tiantan vaccine trials in China.
    Yuan Z; Chen W; Zhang J; Zhang J; Xiang T; Hu J; Wu Z; Du X; Huang A; Zheng J
    Clin Biochem; 2012 Oct; 45(15):1219-24. PubMed ID: 22627200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Protective mucosal immunity and HIV-1 mucosal vaccine strategy].
    Huang Y; Huang XG; Xu JQ
    Bing Du Xue Bao; 2009 Jul; 25(4):318-22. PubMed ID: 19769168
    [No Abstract]   [Full Text] [Related]  

  • 24. Does HIV-2 infection provide cross-protection against HIV-1 infection?
    Ariyoshi K; Schim van der Loeff M; Sabally S; Cham F; Corrah T; Whittle H
    AIDS; 1997 Jul; 11(8):1053-4. PubMed ID: 9223741
    [No Abstract]   [Full Text] [Related]  

  • 25. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxic T-cell recognition of HIV proteins and peptides.
    Nixon DF; McMichael AJ
    AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV-2 vaccine trials in cynomolgus monkeys.
    Biberfeld G; Thorstensson R; Putkonen P
    Antibiot Chemother (1971); 1996; 48():113-20. PubMed ID: 8726513
    [No Abstract]   [Full Text] [Related]  

  • 28. Introduction: HIV neutralizing antibodies: relevance to pathogenesis and vaccines.
    Albert J; Chiodi F; Fenyö EM
    J Intern Med; 2007 Jul; 262(1):2-4. PubMed ID: 17598811
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV Interaction With Human Host: HIV-2 As a Model of a Less Virulent Infection.
    Azevedo-Pereira JM; Santos-Costa Q
    AIDS Rev; 2016; 18(1):44-53. PubMed ID: 26936760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-2 infection and HIV-1/HIV-2 dual reactivity in patients with and without AIDS-related symptoms in Gabon.
    Tevi-Benissan C; Okome M; Makuwa M; Nkoume MN; Lansoud-Soukate J; Georges A; Georges-Courbot MC; Belec L
    Emerg Infect Dis; 1998; 4(1):130-1. PubMed ID: 9452410
    [No Abstract]   [Full Text] [Related]  

  • 31. New research in HIV immunity points way for vaccine.
    Rees J
    Expert Rev Clin Immunol; 2013 May; 9(5):403. PubMed ID: 23772447
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV/AIDS: allied responses.
    Mascola JR
    Nature; 2007 Sep; 449(7158):29-30. PubMed ID: 17805280
    [No Abstract]   [Full Text] [Related]  

  • 33. Challenges in the development of an HIV-1 vaccine.
    Barouch DH
    Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.
    Belyakov IM; Ahlers JD
    Curr Top Microbiol Immunol; 2012; 354():157-79. PubMed ID: 21203884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal.
    Zheng NN; Kiviat NB; Sow PS; Hawes SE; Wilson A; Diallo-Agne H; Critchlow CW; Gottlieb GS; Musey L; McElrath MJ
    J Virol; 2004 Dec; 78(24):13934-42. PubMed ID: 15564501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in the development of an effective HIV vaccine: current approaches and future directions.
    Klein E; Ho RJ
    Clin Ther; 2000 Mar; 22(3):295-314; discussion 265. PubMed ID: 10963285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New strategies to combat HIV: augmenting antiviral immunity.
    Smith KA; Boyle BA
    AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of cytotoxic T-cells in HIV infection.
    Rowland-Jones S; Dong T; Krausa P; Sutton J; Newell H; Ariyoshi K; Gotch F; Sabally S; Corrah T; Kimani J; MacDonald K; Plummer F; Ndinya-Achola J; Whittle H; McMichael A
    Dev Biol Stand; 1998; 92():209-14. PubMed ID: 9554277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines and immunology: elucidating immunity to HIV-1 and current prospects for AIDS vaccine development.
    Heeney JL; Hahn BH
    AIDS; 2000; 14 Suppl 3():S125-7. PubMed ID: 11086855
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.